Guggenheim raised the firm’s price target on Johnson & Johnson to $162 from $156 and keeps a Neutral rating on the shares. The firm is updating its J&J model following Q3 results, driven by the company’s results and updated FY24 guidance, noting that its raised target is mainly driven by modest increases in sales estimates for several products in the Innovative Medicines segment, partially offset by modestly reduced sales estimates in MedTech.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Roblox, Peloton upgraded: Wall Street’s top analyst calls
- Option Care Health downgraded to Neutral at Goldman on Stelara headwinds
- Johnson & Johnson says EC approves expanded use of Edurant in younger patients
- Johnson & Johnson says Impella ECP met primary endpoint in high-risk PCI study
- Johnson & Johnson’s Tremfya shows efficacy in Crohn’s disease Phase 3 study